EUVIMEDEUVIMED entdecken
Crossref

Gastrin-releasing peptide receptor antagonist RC-3095 inhibits Porphyromonas gingivalis lipopolysaccharide-accelerated atherosclerosis by suppressing inflammatory responses in endothelial cells and macrophages

Hyun-Joo Park, Mi-Kyoung Kim, Yeon Kim, Hyung Joon Kim, Hae Ryoun Park, Soo-Kyung Bae, Moon-Kyoung Bae

Inflammation Research · 2024

DOI: 10.1007/s00011-024-01934-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammation Research, 2024. Verfasst von Hyun-Joo Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Physiology, School of Dentistry, Pusan National University, Yangsan, 50612, South Korea. Hauptthemen laut MEDLINE: Atherosclerosis, Porphyromonas gingivalis, Lipopolysaccharides, Macrophages. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Research Foundation of Korea, funded by the Korean government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Porphyromonas gingivalis (P. gingivalis), one of the major periodontopathogens, is associated with the progression and exacerbation of atherosclerosis. In this study, we aimed to investigate whether the gastrin-releasing peptide receptor antagonist, RC-3095, could attenuate P. gingivalis LPS-induced inflammatory responses in endothelial cells and macrophages, as well as atherosclerosis in an ApoE-/- mouse model treated with P. gingivalis LPS. METHODS: The effect of RC-3095 on P. gingivalis LPS-induced endothelial inflammation was examined using HUVECs and rat aortic endothelium. THP-1 cells were polarized into M1 macrophages by exposure to P. gingivalis LPS, with or without RC-3095. The effect of RC-3095 on atherosclerosis progression was assessed in high-fat-fed male ApoE-/- mice through injections of P. gingivalis LPS, RC-3095, or a combination of both. RESULTS: RC-3095 significantly reduced P. gingivalis LPS-induced leukocyte adhesion to endothelial cells and aortic endothelium by suppressing NF-κB-dependent expressions of ICAM-1 and VCAM-1. In addition, RC-3095 inhibited the P. gingivalis LPS-induced polarization of M1 macrophages by blocking the MAPK and NF-κB signaling pathways. Moreover, RC-3095 decreased the area of atherosclerotic lesions in ApoE-/- mice, which was accelerated by P. gingivalis LPS injection, and lowered the expressions of ICAM-1 and VCAM-1 in the aortic tissue of mice with atherosclerosis. CONCLUSIONS: RC-3095 can alleviate P. gingivalis LPS-induced endothelial inflammation, macrophage polarization, and atherosclerosis progression, suggesting its potential as a therapeutic approach for periodontal pathogen-associated atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisPorphyromonas gingivalisLipopolysaccharidesMacrophagesHuman Umbilical Vein Endothelial CellsPeptide FragmentsAnimalsMaleHumansReceptors, BombesinMice, Inbred C57BLMiceTHP-1 CellsRatsNF-kappa BAortaInflammationEndothelial CellsApolipoproteins ERats, Sprague-DawleyBombesin

Stichwörter der Autor:innen

Porphyromonas gingivalisAtherosclerosisGastrin-releasing peptide receptorLipopolysaccharideRC-3095

Substanzen

Lipopolysaccharidesbombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-Peptide FragmentsReceptors, BombesinNF-kappa BApolipoproteins EBombesin

Autor:innen und Institutionen

  • Department of Oral Physiology, School of Dentistry, Pusan National University, Yangsan, 50612, South Korea.
  • Periodontal Disease Signaling Network Research Center (MRC), School of Dentistry, Pusan National University, Yangsan, 50612, South Korea.
  • Dental and Life Science Institute, School of Dentistry, Pusan National University, Yangsan, 50612, South Korea.
  • Department of Oral Pathology, School of Dentistry, Pusan National University, Yangsan, 50610, Korea.
  • Department of Dental Pharmacology, School of Dentistry, Pusan National University, Yangsan, 50612, South Korea.
  • Department of Oral Physiology, School of Dentistry, Pusan National University, Yangsan, 50612, South Korea. mkbae@pusan.ac.kr.

Förderung

  • National Research Foundation of Korea, funded by the Korean government

Zitieren

APA

Park, H. J., Kim, M. K., Kim, Y., Kim, H. J., Park, H. R., Bae, S. K., & Bae, M. K. (2024). Gastrin-releasing peptide receptor antagonist RC-3095 inhibits Porphyromonas gingivalis lipopolysaccharide-accelerated atherosclerosis by suppressing inflammatory responses in endothelial cells and macrophages. Inflammation Research. https://doi.org/10.1007/s00011-024-01934-0

Vancouver

Park HJ, Kim MK, Kim Y, Kim HJ, Park HR, Bae SK, et al. Gastrin-releasing peptide receptor antagonist RC-3095 inhibits Porphyromonas gingivalis lipopolysaccharide-accelerated atherosclerosis by suppressing inflammatory responses in endothelial cells and macrophages. Inflammation Research. 2024. doi:10.1007/s00011-024-01934-0

BibTeX
@article{Park2024,
  author = {Park, Hyun-Joo and Kim, Mi-Kyoung and Kim, Yeon and Kim, Hyung Joon and Park, Hae Ryoun and Bae, Soo-Kyung and Bae, Moon-Kyoung},
  title = {Gastrin-releasing peptide receptor antagonist RC-3095 inhibits Porphyromonas gingivalis lipopolysaccharide-accelerated atherosclerosis by suppressing inflammatory responses in endothelial cells and macrophages},
  journal = {Inflammation Research},
  year = {2024},
  doi = {10.1007/s00011-024-01934-0}
}
Kostenlos starten →